HTFL −17%: beat-and-raise sold hard as Q4 implied guide looks light
Posted: Fri Nov 13, 2026 7:21 pm
Heartflow (HTFL) is a textbook "great quarter, stock down" case today. Shares are off about 16–18%, trading near $49 vs Thursday's $59.92 close.
What happened:
- Q3 revenue $72.9m, up 57% y/y, vs ~$65.2m expected. Adjusted EPS −3c vs a much deeper expected loss.
- The full-year revenue outlook was raised, but the raise implies a noticeably slower Q4 growth pace. That's the part the market is focusing on.
- The stock had run into the print: it set a 52-week high around $60.66 on 11 Nov.
- Stifel ($70), Canaccord ($69) and Baird ($68) all raised targets this morning, and it still sold off. Some chatter about a ~$2.2m CEO sale, though that was under a pre-arranged plan to cover taxes on vested awards.
- It opened around $56.5 and has trended down all day to lows near $48.7. No real bounce so far.
For scalpers: a high-beta (around 2.5) medtech name gapping down on "guidance math" after a run-up. Trend days like this often close near the lows. The reflex bounce usually comes when the stock reclaims VWAP, and there's been no sign of that yet. Volume has been below average for most of the day, so the move could have more to go or bounce sharply on thin liquidity.
Sources: [MassDevice](https://www.massdevice.com/heartflow-st ... ectations/), [WSO](https://wallstreetobserver.com/articles ... nings-drop). Not advice.
Do you fade "beat but implied guide light" gaps, or wait for day two? And do analyst PT raises on a red day mean anything to you intraday?
What happened:
- Q3 revenue $72.9m, up 57% y/y, vs ~$65.2m expected. Adjusted EPS −3c vs a much deeper expected loss.
- The full-year revenue outlook was raised, but the raise implies a noticeably slower Q4 growth pace. That's the part the market is focusing on.
- The stock had run into the print: it set a 52-week high around $60.66 on 11 Nov.
- Stifel ($70), Canaccord ($69) and Baird ($68) all raised targets this morning, and it still sold off. Some chatter about a ~$2.2m CEO sale, though that was under a pre-arranged plan to cover taxes on vested awards.
- It opened around $56.5 and has trended down all day to lows near $48.7. No real bounce so far.
For scalpers: a high-beta (around 2.5) medtech name gapping down on "guidance math" after a run-up. Trend days like this often close near the lows. The reflex bounce usually comes when the stock reclaims VWAP, and there's been no sign of that yet. Volume has been below average for most of the day, so the move could have more to go or bounce sharply on thin liquidity.
Sources: [MassDevice](https://www.massdevice.com/heartflow-st ... ectations/), [WSO](https://wallstreetobserver.com/articles ... nings-drop). Not advice.
Do you fade "beat but implied guide light" gaps, or wait for day two? And do analyst PT raises on a red day mean anything to you intraday?